Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp DBC instrument

Agreement will allow researchers to streamline development of on-demand and automated production of CRISPR-Cas9 guide RNASAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader

Related Keywords

San Diego ,California ,United States ,Bio Bioxp ,Kostenloser Wertpapierhandel ,Toddr Nelson ,Charlie Schmidt ,Ben Chiarelli ,Exchange Commission ,Gibson Assembly ,Telesis Bio ,Biological Converter ,Digital To Biological Converter ,Private Securities Litigation Reform Act ,Telesis ,Cellibre ,Nnounce ,Collaboration ,Optimize ,Development ,Future ,Ioxp ,Instrument ,